Log In
BCIQ
Print this Print this
 

margetuximab (MGAH22)

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionFc optimized mAb against HER2
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/22/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today